Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Hutchison China MediaTech reports record 2016 revenue as commercial sales rise

Monday, March 13, 2017 2:22
% of readers think this story is Fact. Add your two cents.

Hutchison China MediTech Limited (LON:HCM), which makes drugs for the treatment of cancer, said it achieved record revenues in 2016, driven by commercial sales.

Revenue rose 21% to $216.1mln in the year to 31 December 2016 from $178.2mln a year earlier, as a 43% increase in commercial platform revenue offset a 32% decline in innovation platform revenue.

The commercial platform business was boosted by its consolidated joint venture Hutchison Whampoa Sinopharm Pharmaceuticals Company Ltd in Shanghai, which supplies prescription drugs.

Net income increased 46% to $11.7mln from $8.0mln, even as research and development expenses rose to $76.1mln from $55.8mln.

During the period, the company said it had accelerated and expanded work on c-MET inhibitor candidate savolitinib through an amended license deal with AstraZeneca (LON:AZN) that covers a Phase III global trial for treatment of kidney, lung and gastric cancers.

Under the amended deal with AstraZeneca in August, Chi-Med agreed to provide up to $50mln for the joint-development costs of savolitinib in return for a five percentage point increase in royalties payable on the drug’s sales across indications in all markets outside of China.

The company reported positive results from the phase III study of fruquintinib for the treatment of colorectal cancer and expects to launch the product in 2018.

Hutchison is also conducting phase I studies on multiple novel drug candidates including HMPL-523 against spleen tyrosine kinase and HMPL-453 against fibroblast growth factor receptors.

At the end of the year the group held cash resources of $173.7mln, compared to $38.8mln the prior year, which Hutchison believes is sufficient to fund its activities, including the increased cash requirements following the amendment to the savolitinib collaboration with AstraZeneca.

Shares rose 3.54% to 2,498p  in morning trading.  

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.